| 1 |
Ren A, Tong X, Xu N, Zhang T, Zhou F, Zhu H. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines (Basel) 2023;11. [PMID: 36680011 DOI: 10.3390/vaccines11010165] [Reference Citation Analysis]
|
| 2 |
Sandal R, Chauhan A, Jandial A, Mishra K, Rastogi P, Dhiman P, Kumar A. Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Natural History, and Management in the Current Era. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2022_114] [Reference Citation Analysis]
|
| 3 |
Luo L, Zhou X, Zhou L, Liang Z, Yang J, Tu S, Li Y. Current state of CAR-T therapy for T-cell malignancies. Ther Adv Hematol 2022;13:20406207221143025. [PMID: 36601636 DOI: 10.1177/20406207221143025] [Reference Citation Analysis]
|
| 4 |
Wang L, Ji K, Chen L, Li Y, Zhu W, Yuan X, Bao X, Wu X, He J. Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies. Front Immunol 2022;13:1047200. [PMID: 36532004 DOI: 10.3389/fimmu.2022.1047200] [Reference Citation Analysis]
|
| 5 |
Rebmann E, Nabergoj M, Grandjean B, Stakia P, Stern A, Medinger M, Masouridi-Levrat S, Dantin C, Schanz U, Baldomero H, Passweg J, Nair G, Rovo A, Chalandon Y. Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better. EJHaem 2023;4:258-61. [PMID: 36819159 DOI: 10.1002/jha2.614] [Reference Citation Analysis]
|
| 6 |
Li F, Zhang H, Wang W, Yang P, Huang Y, Zhang J, Yan Y, Wang Y, Ding X, Liang J, Qi X, Li M, Han P, Zhang X, Wang X, Cao J, Fu YX, Yang X. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun 2022;13:4334. [PMID: 35882880 DOI: 10.1038/s41467-022-32092-8] [Reference Citation Analysis]
|
| 7 |
Miyazaki M, Ichikawa S, Onishi Y, Fukuhara N, Furukawa E, Onodera K, Yokoyama H, Ichinohasama R, Harigae H. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation. J Clin Exp Hematop 2022. [PMID: 35732409 DOI: 10.3960/jslrt.22003] [Reference Citation Analysis]
|
| 8 |
Ichikawa S, Fukuhara N, Doman T, Kiba D, Tanaka Y, Inokura K, Morota N, Ono K, Onodera K, Onishi Y, Yokoyama H, Ichinohasama R, Harigae H. Aleukemic T-lymphoblastic leukemia/lymphoma with massive cerebrospinal fluid infiltration. J Hematopathol. [DOI: 10.1007/s12308-022-00495-7] [Reference Citation Analysis]
|
| 9 |
Zhao W, Yang J, Liao Y, Lao HY, Huang Q, Jin L, Sun J, Huang F, Liang L. Comparable meibomian gland changes in patients with and without ocular graft-versus-host disease after hematopoietic stem cell transplantation. Ocul Surf 2022:S1542-0124(22)00022-2. [PMID: 35395386 DOI: 10.1016/j.jtos.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Kameda K, Kako S, Kim S, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida S, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. [DOI: 10.1038/s41375-022-01545-w] [Reference Citation Analysis]
|
| 11 |
Dai N, Liu H, Deng S, Sang S, Wu Y. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival. Technol Cancer Res Treat 2021;20:15330338211056478. [PMID: 34806464 DOI: 10.1177/15330338211056478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Lasagni Vitar RM, Bonelli F, Atay A, Triani F, Fonteyne P, Di Simone E, Rama P, Mondino A, Ferrari G. Topical neurokinin-1 receptor antagonist Fosaprepitant ameliorates ocular graft-versus-host disease in a preclinical mouse model. Exp Eye Res 2021;212:108825. [PMID: 34740637 DOI: 10.1016/j.exer.2021.108825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 13 |
Gu ZY, Dong YJ, Fu XR, Li NN, Liu Y, Wu XX, Wang YN, Li YH, Ren HY, Zhang MZ, Li XF, Wang MH, Wu YM, Liu DH, Wang Z, Hu LD, Huang WR. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. Chin Med J (Engl) 2021;134:1584-92. [PMID: 34133361 DOI: 10.1097/CM9.0000000000001575] [Reference Citation Analysis]
|
| 14 |
Dreger P. Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication? Hematol Oncol 2021;39 Suppl 1:100-3. [PMID: 34105814 DOI: 10.1002/hon.2845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 15 |
Chong EA, Porter DL. Immunotherapy with cells. Hematology Am Soc Hematol Educ Program 2020;2020:590-7. [PMID: 33275723 DOI: 10.1182/hematology.2020000174] [Reference Citation Analysis]
|
| 16 |
Gao H, Ji X, Liu X, Mi L, Liu W, Wang X, Zhu J, Song Y. Conditional survival and hazards of death for peripheral T-cell lymphomas. Aging (Albany NY) 2021;13:10225-39. [PMID: 33819191 DOI: 10.18632/aging.202782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 17 |
Zhenyang G, Nainong L, Xiaoxiong W, Maihong W, Xiaorui F, Zhao W, Hanyun R, Yuhang L, Xiaofan L, Yamei W, Yao L, Mingzhi Z, Yini W, Daihong L, Yujun D, Liangding H, Wenrong H. Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas. Cell Transplant 2021;30:963689721999615. [PMID: 33745341 DOI: 10.1177/0963689721999615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Lam W, Nag A, Kumar R. Outcomes of Bone Marrow Transplantation. Contemporary Bone Marrow Transplantation 2021. [DOI: 10.1007/978-3-030-36358-1_5] [Reference Citation Analysis]
|
| 19 |
Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 20 |
Fuji S, Kida S, Nakata K, Morishima T, Miyashiro I, Ishikawa J. Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry. Ann Hematol 2021;100:157-65. [PMID: 33089366 DOI: 10.1007/s00277-020-04308-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 21 |
Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Res 2020;9:F1000 Faculty Rev-1091. [PMID: 32934797 DOI: 10.12688/f1000research.22257.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 22 |
Bachy E, Broccoli A, Dearden C, de Leval L, Gaulard P, Koch R, Morschhauser F, Trümper L, Zinzani PL. Controversies in the Treatment of Peripheral T-cell Lymphoma. Hemasphere 2020;4:e461. [PMID: 33062943 DOI: 10.1097/HS9.0000000000000461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Galtier J, Parrens M, Milpied N. [Peripheral T cell lymphomas: diagnosis and treatment]. Rev Med Interne 2020;41:829-37. [PMID: 32674892 DOI: 10.1016/j.revmed.2020.05.015] [Reference Citation Analysis]
|
| 24 |
Selberg L, Stadtherr P, Dietrich S, Tran TH, Luft T, Hegenbart U, Bondong A, Meissner J, Liebers N, Schmitt M, Ho AD, Müller-Tidow C, Dreger P. The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. Bone Marrow Transplant 2021;56:30-7. [PMID: 32555407 DOI: 10.1038/s41409-020-0976-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 25 |
Mamez AC, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, Mohty M, Suarez F, Beguin Y, Peffault De Latour R, Rubio MT, Tournilhac O, Nguyen S. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). J Hematol Oncol 2020;13:56. [PMID: 32429979 DOI: 10.1186/s13045-020-00892-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 26 |
Allen PB, Pro B. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes. Curr Oncol Rep 2020;22:44. [PMID: 32297075 DOI: 10.1007/s11912-020-00902-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Schmitz C, Rekowski J, Müller SP, Hertenstein B, Franzius C, Ganser A, Bengel FM, Kroschinsky F, Kotzerke J, La Rosée P, Freesmeyer M, Hoeffkes HG, Hertel A, Behringer D, Mesters R, Weckesser M, Mahlmann S, Haberkorn U, Martens U, Prange-Krex G, Brenner W, Giagounidis A, Moeller R, Runde V, Sandmann M, Hautzel H, Wilop S, Krohn T, Dürk H, Heike M, Alashkar F, Brinkmann M, Trenn G, Wacker D, Kreisel-Büstgens C, Bernhard H, Heil G, Larisch R, Kurch L, Jöckel KH, Hoelzer D, Klapper W, Boellaard R, Dührsen U, Hüttmann A. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Hematol Oncol 2020;38:244-56. [PMID: 32067259 DOI: 10.1002/hon.2697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 28 |
Lam W, Nag A, Kumar R. Outcomes of Bone Marrow Transplantation. Contemporary Bone Marrow Transplantation 2020. [DOI: 10.1007/978-3-319-64938-2_5-1] [Reference Citation Analysis]
|
| 29 |
Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J 2019;9:97. [PMID: 31796726 DOI: 10.1038/s41408-019-0261-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 30 |
Wulf G, Weber T. Periphere T‑Zell-Lymphome. Onkologe 2019;25:892-898. [DOI: 10.1007/s00761-019-0636-8] [Reference Citation Analysis]
|
| 31 |
Zhao WL, Cai MC. [How I diagnose and treat peripheral T cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:363-7. [PMID: 31207698 DOI: 10.3760/cma.j.issn.0253-2727.2019.05.003] [Reference Citation Analysis]
|
| 32 |
Somasundaram N, Thye Lim S. Overview of T-cell Lymphomas. Peripheral T-cell Lymphomas 2019. [DOI: 10.5772/intechopen.85058] [Reference Citation Analysis]
|
| 33 |
Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ. Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma? Curr Oncol Rep 2019;21:65. [PMID: 31183579 DOI: 10.1007/s11912-019-0809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 34 |
Hunter BD, Chen YB, Jacobson CA. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. Hematol Oncol Clin North Am 2019;33:687-705. [PMID: 31229163 DOI: 10.1016/j.hoc.2019.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 35 |
Scherer LD, Brenner MK, Mamonkin M. Chimeric Antigen Receptors for T-Cell Malignancies. Front Oncol 2019;9:126. [PMID: 30891427 DOI: 10.3389/fonc.2019.00126] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 36 |
Narra RK, Shah NN. Allogenic Transplant for Non-Hodgkin Lymphoma. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00015-8] [Reference Citation Analysis]
|
| 37 |
Hübel K, Montoto S. Other T- and B-Aggressive Lymphomas and Lymphomas Associated with HIV. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 647-51. [DOI: 10.1007/978-3-030-02278-5_87] [Reference Citation Analysis]
|
| 38 |
Gu Z, Wang L, Wang Q, Li H, Bo J, Wang S, Zhao Y, Li F, Gao C, Liu D, Huang W. Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. Ann Hematol 2019;98:1237-47. [PMID: 30539277 DOI: 10.1007/s00277-018-3559-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 39 |
McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 2018;132:2351-61. [PMID: 30262660 DOI: 10.1182/blood-2018-07-863654] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
|
